Ong CT, Tessier P, Li C, Nightingale CH, Nicolau DP. Comparative Efficacy of Meropenem, Imipenem, and Cefepime Against Pseudomonas aeruginosa Expressing MexA-Mex B-OprM Efflux Pumps. Diagnos Microb Infect Dis. 2007; 57:153-161.
Kuti J, Ong C, Lo M, Melnick D, Soto N, Nicolau DP. Comparison of Pharmacodynamic Target Attainment Calculated by Monte Carlo Simulation with Microbiological Response for the Treatment of Complicated Skin and Skin Structure Infections. Int J Antimicrob Agents. 2006; 28:62-68.
Ong CT, Kuti JL, Nicolau DP. Pharmacodynamic Analysis of Imipenem-cilastatin, Meropenem, and Piperacillin-Tazobactam for Empiric Therapy in Surgical Wound Infections: A Report from the OPTAMA Study. Surgical Infect. 2005; 6(4):419-426
Ong CT, Dandekar P, Sutherland C, Nightingale CH, Nicolau DP. Bronchopulmonary Pharmacokinetics of Telithromycin: Clinical Implications with Streptococcus pneumoniae. Chemotherapy. 2005; 51(6):339-46.
Ong CT, Babalola CP, Nightingale CH, Nicolau DP. Penetration, Efflux, and Activity of Tigecycline in Human Polymorphonuclear Neutrophils (PMNs). J Antimicrob Chemother. July 15, 2005.
Sun H, Ong CT, Nightingale CH, Nicolau DP. Tigecycline Pharmacokinetic Profile in Serum and Blister Fluid after Multiple Intravenous Administration in Healthy Adults. Antimicrob Agents Chemother. 2005; 49(4):1629-1632.
Fetterly G, Ong CT, Bhavnani S, Loutit J, Ambrose P, Nicolau DP. A Single-Center, Open-Label Phase I Trial Evaluating the Pharmacokinetics and Tissue Penetration of Oritavancin in Normal Healthy Volunteers. J Antimicrob Chemother. 2005; 49(1):148-152.
Ong CT, Kuti J, Nightingale CH, Nicolau DP. Emerging Pseudomonas aeruginosa Resistance: Implications in Clinical Practice. Conn Medicine. 2004; 68(1):11-15.
Ong CT, Nicolau DP. Rationale and Utility of Therapeutic Drug Monitoring for the Optimization Antibiotic Therapy. Drug Monitoring and Clinical Chemistry: Handbook of Analytical Separations. 5:195-219, 2004.
Maglio D, Ong CT, Banevicius M, Geng Q, Nightingale CH, Nicolau DP. Determination of the In Vivo Pharmacodynamic Profile of Cefepime Against Extended-Spectrum Beta-Lactamase Producing Escherichia coli at Various Inocula. Antimicrob Agents Chemother. 2004; 48:1941-1947.